Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.
2.

Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection.

Cui JC, Hu DL, Lin YC, Qian AD, Nakane A.

FEMS Immunol Med Microbiol. 2005 Jul 1;45(1):45-51. Epub 2005 Feb 10.

3.

Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection.

Hu DL, Omoe K, Sasaki S, Sashinami H, Sakuraba H, Yokomizo Y, Shinagawa K, Nakane A.

J Infect Dis. 2003 Sep 1;188(5):743-52. Epub 2003 Aug 14.

PMID:
12934191
4.

Vaccination with non-toxic mutant toxic shock syndrome toxin-1 induces IL-17-dependent protection against Staphylococcus aureus infection.

Narita K, Hu DL, Asano K, Nakane A.

Pathog Dis. 2015 Jun;73(4). pii: ftv023. doi: 10.1093/femspd/ftv023. Epub 2015 Apr 9.

PMID:
25857736
5.

Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses.

Spaulding AR, Lin YC, Merriman JA, Brosnahan AJ, Peterson ML, Schlievert PM.

Vaccine. 2012 Jul 20;30(34):5099-109. doi: 10.1016/j.vaccine.2012.05.067. Epub 2012 Jun 9.

6.

[Neutralizing activity of human immunoglobulin preparation against toxic shock syndrome toxin-1].

Nakae T, Hirayama F, Hashimoto M.

Kansenshogaku Zasshi. 2002 Mar;76(3):195-202. Japanese.

PMID:
11974889
7.

Intranasal immunization of mutant toxic shock syndrome toxin 1 elicits systemic and mucosal immune response against Staphylococcus aureus infection.

Narita K, Hu DL, Tsuji T, Nakane A.

FEMS Immunol Med Microbiol. 2008 Apr;52(3):389-96. doi: 10.1111/j.1574-695X.2008.00384.x. Epub 2008 Feb 27.

9.

Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1.

Rukkawattanakul T, Sookrung N, Seesuay W, Onlamoon N, Diraphat P, Chaicumpa W, Indrawattana N.

Toxins (Basel). 2017 Feb 17;9(2). pii: E50. doi: 10.3390/toxins9020050.

10.

Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection.

Hu DL, Omoe K, Narita K, Cui JC, Shinagawa K, Nakane A.

Microbes Infect. 2006 Nov-Dec;8(14-15):2841-8. Epub 2006 Oct 11.

PMID:
17090392
11.

Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1.

Miethke T, Duschek K, Wahl C, Heeg K, Wagner H.

Eur J Immunol. 1993 Jul;23(7):1494-500.

PMID:
8325325
13.

Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig.

Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R.

J Immunol. 1996 Nov 1;157(9):3869-75.

PMID:
8892617
14.

Inverse relationship between toxic shock syndrome toxin-1 antibodies and interferon-γ and interleukin-6 in peripheral blood mononuclear cells from patients with pediatric tonsillitis caused by Staphylococcus aureus.

Chen Y, Huang Y, Liang B, Dong H, Yao S, Xie Y, Long Y, Zhong H, Yang Y, Zhu B, Gong S, Zhou Z.

Int J Pediatr Otorhinolaryngol. 2017 Jun;97:211-217. doi: 10.1016/j.ijporl.2017.04.019. Epub 2017 Apr 12.

PMID:
28483238
16.

Toxic shock syndrome: characterization of human immune responses to TSST-1 and evidence for sensitivity thresholds.

Kimber I, Nookala S, Davis CC, Gerberick GF, Tucker H, Foertsch LM, Dearman RJ, Parsonnet J, Goering RV, Modern P, Donnellen M, Morel J, Kotb M.

Toxicol Sci. 2013 Jul;134(1):49-63. doi: 10.1093/toxsci/kft099. Epub 2013 May 2.

PMID:
23640863
17.

Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release.

Krakauer T, Stiles BG.

Clin Diagn Lab Immunol. 1999 Jul;6(4):594-8.

18.

Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome.

Kansal R, Davis C, Hansmann M, Seymour J, Parsonnet J, Modern P, Gilbert S, Kotb M.

J Clin Immunol. 2007 May;27(3):327-38. Epub 2007 Mar 6.

PMID:
17340193
19.

Toxic shock syndrome toxin-1 (TSST-1) antibody levels in Japanese children.

Quan L, Morita R, Kawakami S.

Burns. 2010 Aug;36(5):716-21. doi: 10.1016/j.burns.2009.10.004. Epub 2009 Dec 24.

PMID:
20036064

Supplemental Content

Support Center